Stellenwert von Baricitinib in der neuen S2e-Leitlinie zur rheumatoiden Arthritis
Crossref DOI link: https://doi.org/10.1007/s15002-019-1539-1
Published Online: 2019-02-16
Published Print: 2019-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kathmann, Wiebke
Text and Data Mining valid from 2019-02-01
Article History
First Online: 16 February 2019